相关实验视频

Updated: Jan 11, 2026

Author Spotlight: Investigating Physiological Functions of Vitamin A Transporters Using HPLC-Based Vitamin A Profiling

Author Spotlight: Investigating Physiological Functions of Vitamin A Transporters Using HPLC-Based Vitamin A Profiling

Published on: December 27, 2024

通过向aldehyde dehydrogenase 1A3 向甲脱酶1A3 开发类核受体通路抗剂

Mark Esposito^1,2,3, Cao Fang^1,3, Yong Wei^1,3

¹Department of Molecular Biology, Princeton University, Princeton, NJ 08544, USA.

|November 10, 2025

概括

化脱酶1a3 (ALDH1A3) 通过抑制通过膜信号传递的抗瘤免疫力来驱动癌症. 研究人员开发了新的ALDH1A3抑制剂,为癌症治疗提供了新的治疗策略.

科学领域:

生物化学生物化学
免疫学免疫学免疫学
在瘤学瘤学.

背景情况:

阿尔德脱酶1a3 (ALDH1A3) 与心脏代谢疾病和癌症有关.
它在疾病进展中的精确作用和缺乏有效的抑制剂仍然是重大挑战.
矛盾的是,ALDH1A酶在将视网甲转化为全跨视网酸 (atRA) 的正规功能与瘤抑制有关.

研究的目的:

阐明ALDH1A3在癌症中的悖论性作用.
研究ALDH1A3促进瘤发生的机制.
确定和开发ALDH1A3.3的新型治疗抑制剂.

主要方法:

采用了混合的in silico和高通量选方法.
对已识别的化合物进行药用优化.
评估ALDH1A3抗剂的抗瘤免疫治疗活性.

主要成果:

在各种癌症中,ALDH1A3过度表达,瘤细胞对视网体信号传递的敏感性降低.
来自ALDH1A3的atRA通过激活免疫细胞中的视网体信号来抑制抗瘤免疫力.
确定了第一类,口服和安全的ALDH1A3抗体,具有强大的抗瘤免疫治疗活性.

结论:

ALDH1A3通过对膜抑制抗瘤免疫来促进癌症的进展,解决了它在癌症中的作用的悖论.
开发的新型ALDH1A3抗剂代表了癌症治疗的有前途的新型免疫疗法药物.
已识别的抑制剂具有针对临床转化进行优化药物开发的概况.

关键词:

癌症癌症癌症癌症细胞生物学细胞生物学

更多相关视频

Application of AlDeSense to Stratify Ovarian Cancer Cells Based on Aldehyde Dehydrogenase 1A1 Activity

Application of AlDeSense to Stratify Ovarian Cancer Cells Based on Aldehyde Dehydrogenase 1A1 Activity

Published on: March 31, 2023

Author Spotlight: Unraveling Vitamin A Transport Mechanisms — Linking Liver Receptors to Vision Health Through RBPR2 and RBP4 Interactions

Author Spotlight: Unraveling Vitamin A Transport Mechanisms — Linking Liver Receptors to Vision Health Through RBPR2 and RBP4 Interactions

Published on: October 4, 2024

相关概念视频

Transducer Mechanism: Nuclear Receptors

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:

Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems

Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems

Phase I biotransformation reactions are integral to drug metabolism, predominantly involving oxidative, reductive, and hydrolytic transformations. Chief among these are oxidative reactions, which enhance the hydrophilicity of xenobiotics and introduce polar functional groups to facilitate their elimination from the body.
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...

Phase I Reactions: Reductive Reactions

Phase I Reactions: Reductive Reactions

Phase I biotransformation reductive reactions are chemical processes that modify drugs by introducing or revealing polar functional groups via reduction. Enzymes called reductases catalyze these reactions, playing a pivotal role in drug metabolism by transforming lipophilic drugs into more polar, water-soluble metabolites for easy excretion. An essential type of reductive reaction is the carbonyl group reduction, where aldehydes and ketones are reduced to alcohols. An example is the...